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ABSTRACT 
It is increasingly being recognized that well-being after successful cancer treatment consists 
of more than a mere lowering of risk for disease recurrence. Cancer survival can be 
characterized by uncertainty, fear, and the interpretation of bodily sensations as potentially 
symptomatic. This fear can lead to vigilance for bodily sensations and precautionary visits to 
the doctor, both of which may increase the chance of early detection but may also increase 
anxiety and decrease quality of life. In this Personal View article, we consider the medical, 
psychological, and ethical issues surrounding the practice of self-directed symptom 
monitoring after successful cancer treatment, focusing on the role of doctor-patient 
communication. We ask how clinicians can make room for the plurality of values that 
patients might bring to the table when it comes to deciding how to manage—and respond 
to—experiences of post-cancer symptoms. We advocate a shared decision-making 
approach that incorporates an assessment of the magnitude of the individual’s cancer 
recurrence risks as well as psychosocial considerations of fear of cancer recurrence and 
mental health. We aim to raise awareness of the potential quality-of-life implications of 
symptom monitoring practices, emphasizing the need for a balance between physical and 
psychological health in cancer survivorship.  
 
1. The problem of symptom appraisal after cancer 
Improvements in treatment and early detection mean that more people are surviving 
cancer than ever before. Now, there is increased attention on how to optimize follow-up 
care, with a focus on not only physical, but also psychological health. The practice of 
symptom monitoring is critical to both but has received relatively little attention. Many, if 
not most individuals living beyond cancer will engage in symptom monitoring practices of 
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some kind, purposefully attending towards and internally scanning their body for 
fluctuations in such sensations as pain, fatigue, and breathlessness. Symptom monitoring is 
most likely pursued with the goal of detecting signs of disease recurrence, second 
malignancies, or late-effects of treatment. These practices may be actively encouraged by 
clinicians or may be entirely self-directed.  
 
Within the context of active cancer treatment, symptom monitoring and reporting has 
generally been shown to have more benefit than harm1,2. However, the phase beyond active 
treatment may be very different. It is typically characterized by a sudden loss of clinical 
contact, a termination of most or all symptom-inducing treatment, and extreme 
psychological uncertainty regarding the late effects of treatment and potential disease 
recurrence3. Thus, ambiguous bodily sensations such as those described above can cause 
fear and anxiety 4–7. Knowing how to appraise and respond to bodily sensations after cancer 
is a central challenge of survivorship5.  
 
How beneficial, then, is ‘symptom monitoring’ after cancer treatment? Here, we focus on 
those individuals who successfully complete active treatment and, although commonly 
under active follow-up and monitoring for recurrence, are considered disease free. The 
answer is not straightforward. First, bodily sensations such as fatigue, itch, pain, poor 
appetite, and breathlessness can indeed be markers of disease recurrence, but can also be 
unreliable. Fluctuating bodily sensations are an ordinary part of everyday life, especially 
after chemotherapy, radiotherapy, and surgery 8–11. Indeed, although we use the term 
‘symptom-monitoring’ in this article, we refer not exclusively to true symptoms of disease 
but more broadly to (often benign) bodily sensations that characterize our daily lives. 
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Second, in many countries, long-term follow-up care involves extensive routine surveillance 
to detect new or recurrent disease in its early stages, before it is symptomatic. In these 
cases, the added practice of symptom monitoring is unlikely to be of medical benefit but can 
still cause psychological harm.  
 
Given that bodily sensations can be untrustworthy as markers of disease, whose constant 
surveillance may not add benefit beyond regular screening, a challenge is raised as to how 
individuals should best monitor, respond to, and report on bodily sensations following 
successful cancer treatment. This challenge is especially relevant given potential (adverse) 
quality of life implications that may be associated with constant and/or heightened self-
surveillance12. It is our suggestion that clinicians working in an oncology context play a 
prominent role in deciding with patients how much to engage in ‘symptom monitoring’ 
practices, taking into consideration the overall quality-of-life implications for the patient 
based on their values and psychological needs. We highlight and discuss the ethical role of 
the oncology clinician in directing patient symptom monitoring practices, asking how 
clinicians can best communicate with patients about this challenge.  
 
Central to this challenge is the following question: Is it better for clinicians to encourage a 
‘better safe than sorry’ approach, counseling patients to present for assessment when 
bodily sensations change? Or is it better to encourage a ‘wait and see’ approach, focusing 
on reducing unproductive worry about the potential negative meanings associated with 
such changes? Of course, this is an oversimplification: it need not be either/or. And the 
‘right’ answer will likely differ depending on different approaches to screening and imaging 
in long-term follow-up programs across countries and clinical settings. But it is worth 
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considering the benefits and risks of placing more or less emphasis on each approach. The 
clinical and ethical challenge, we believe, is in finding a patient-relative position of optimal 
‘vigilance’: neither hyper- nor hypo-vigilant, cautious concern without excessive anxiety or 
avoidance.  
 
2. The case for reducing symptom monitoring 
Clinicians may choose to encourage symptom monitoring to increase odds of survival. 
Especially in countries and clinical settings where cost-effective medicine decisions 
discourage frequent follow-up tests, the patient’s bodily sensations may be a primary guide 
for indications of disease recurrence or secondary cancer. Indeed, encouraging symptom 
monitoring may be included as one component of survivorship care plans. Relatedly, the 
ASCO guidelines for the management of (chronic) pain in people living beyond cancer is to 
“evaluate and monitor for recurrent disease, second malignancy, or late-onset treatment 
effects in any patient who reports new-onset pain” 13. Clinicians may also offer specific 
recommendations for symptom monitoring. For example, a patient may be guided to be 
especially attentive to new, persistent pain in the previous tumor site or in sites of likely 
metastatic disease, rather than simply to monitor all bodily sensations. Thus, when the goal 
is to boost the chance of survival through early detection of disease recurrence and the 
assumption is that (certain) physical symptoms are relevant indicators of disease, symptom 
monitoring is entirely appropriate.  
 
However, one must also consider the psychological context and consequences of symptom 
monitoring. Critical to this is integrating knowledge from decades of research outside of 
oncology revealing that that bodily sensations such as pain are highly modulated by 
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cognitive and contextual variables14–18. Pain is not, as was once commonly believed, a 
simple read-out of the state of the body tissues. Its salience, frequency, and quality can 
change in the face of fear and anxiety19–22 which, in turn, can further increase the 
unreliability of pain as a marker of disease. Of vital importance here is recognition that fear 
and anxiety are very common after cancer. Indeed, fear of cancer recurrence (FCR) is among 
the most commonly reported problems in people living beyond cancer, one of the most 
prevalent areas of unmet need23, and is strongly associated with poor quality of life12. 
Maladaptive health behaviors (including over-surveillance/body checking and under-
surveillance), aversive psychological reactions, and functional impairments have been 
identified as consequences of FCR12. Given that fear and anxiety are shown to worsen pain 
and other sensations, and that fear and anxiety are common after cancer, it is unsurprising 
that the presence of bodily sensations such as pain is repeatedly shown to be associated 
with higher FCR24.  
 
To bring attention to this issue, we recently presented the Cancer Threat Interpretation 
(CTI) model of symptom appraisal in the context of cancer-related uncertainty, reviewing 
the relevant literature and highlighting the cognitive, affective, and behavioral 
consequences of interpreting ambiguous bodily sensations as indicating potential cancer 
recurrence 5. Within the CTI framework, it is possible that even when given specific advice 
about which symptoms to attend to, anxiety and fear may primarily drive the felt 
experience of those symptoms and thus their overall perception as indicating danger. 
Recent research has also revealed that metacognitions, including negative beliefs about 
worry, are associated with increased FCR and may maintain FCR over time25. This is 
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particularly relevant within the context of symptom monitoring, in which individuals can 
hold beliefs that actively worrying about symptoms may increase their chance of survival.  
 
Taken together, when the goal shifts beyond medical considerations to include 
psychological health, reducing symptom monitoring can sometimes be appropriate, 
especially in those for whom it induces severe anxiety. We argue here that any 
consideration of symptom monitoring practices, especially within the context of clinician 
communication about such practices, must include a consideration of the impact that bodily 
symptoms may have on FCR. As we will discuss later, communication regarding symptom 
monitoring practices would be best considered when individual patient level of FCR is 
adequately screened and detected, and thus can be considered within this broader 
psychological context.   
 
3. Striking a balance: shared decision-making in cancer uncertainty  
Given such complexities and trade-offs, how should clinicians communicate about symptom 
monitoring? One answer lies in how we characterize the communication between clinicians 
and patients following successful treatment and moving into long-term follow-up. There is 
increasing consensus among bioethicists of the value of shared decision-making (SDM) in 
clinical encounters as a way of enhancing autonomy. Multiple studies report that integrating 
enhanced SDM improves outcomes, including within cancer contexts 26,27, which supports 
the principle of beneficence. Indeed, the SDM framework is not new in cancer care and has 
been applied to topics such as cancer screening adherence and decisions regarding 
preventative surgery and treatment 28, which also connects SDM to beneficence. It has also 
been applied to the provision of emotional support, such as relieving fear and anxiety and 
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addressing mental health issues during cancer diagnosis and treatment 28. However, less 
research has focused on SDM in the post-treatment, survivorship stage.  
 
SDM has been termed “the pinnacle of patient-centered care” 29. From an ethical 
perspective, strengthening SDM within the context of directed symptom monitoring after 
cancer carries a number of advantages. One advantage is that SDM maximizes patient 
autonomy. People with cancer may feel particularly vulnerable and disempowered, 
especially given a history of cancer treatment in the West that has all-too-often been 
characterized by norms of silence 30.  At times, as in the case of breast cancer, physician-
proponents of one class of interventions (e.g., lumpectomy + radiation vs. prophylactic 
mastectomy) often refused to seriously discuss the harms and benefits of the other option 
in consultation with their patients, with the idea that ‘doctor knows best’ 30. Conversely, 
people in pain often do not share their pain experiences with their doctors (or others): they 
may not want to ‘burden’ others with regular reports of discomfort; or they may even 
experience denial that pain in the context of serious illness could signal something as 
distressing as treatment-refractory recurrence. Accordingly, any approach that allows 
patients to express and engage meaningfully with their experiences strengthens the voice of 
the patient and therefore enhances autonomy. 
 
Another advantage of SDM is that it can promote what is known as ‘epistemic justice’ in 
healthcare encounters. Epistemic justice involves respecting an agent’s legitimacy as a 
knower—especially when it comes to her own subjective experiences, of which pain is a 
paradigm example. In this case, acknowledgment by the clinician that a patient may have 
her own valid concerns regarding clinical and psychological consequences of symptom 
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perception can serve as an important starting point. In the case of chronic non-cancer pain, 
listening to people in pain and taking their experiences seriously is not only essential to 
ensuring epistemic justice, but its absence practically guarantees that they will be 
stigmatized 31,32. Within the context of cancer survival, it is possible that at least some 
reports of pain may be less likely to be outright ignored given their potential clinical 
relevance, but they may also sometimes be inappropriately discounted precisely because 
the clinician is aware that the patient has grounds to be extra-sensitive. There is increasing 
recognition that epistemic justice is an important ethical consideration in health care 
encounters31, and any tool that enhances it is therefore of ethical significance. 
 
On the other side of the coin, individuals who express a desire not to prioritize constant 
vigilance about pain over all other considerations (such as their quality of life in the context 
of their own goals and values) may also have their perspective questioned and may be 
stigmatized, discouraged, or dismissed, in favor of a ‘better safe than sorry’ (or ‘doctor 
knows best’) approach. A nuanced deployment of SDM, by contrast, would begin by helping 
individuals identify and express their particular values, including those that may diverge 
from a preference for hypersensitivity to, and never-ending worry about, the experience of 
pain or other bodily sensations. Indeed, one of the hallmarks of a commitment to SDM in 
health care is an understanding of risk and benefit in pluralistic terms: people can and do 
weigh risks and benefits differently and come to divergent but often entirely reasonable 
decisions 33.  People will value essential dimensions of well-being differently, and these 
differences are paramount when considering the threat of cancer recurrence 34.  
 
10 
 
To guide clinicians in structuring their discussions with individuals living beyond cancer, we 
present in Figure 1 a shared decision-making (SDM) framework for symptom monitoring in 
cancer survival. This framework includes both disease/treatment-related considerations 
(clinician communication about individual risk of recurrence and symptom reliability) as well 
as psychological considerations. It would be optimal if it involved: 
(1) measurement of the patient’s fear and anxiety around cancer recurrence, 
including fear that physical symptoms may be a sign of recurrence  
(2) acknowledgement that the practice of directed symptom monitoring can have 
effects on fear, wellbeing, and quality-of-life  
(3)  an explicit opportunity for the expression of multiple concerns regarding these 
effects, from all relevant agents 
(4) an acknowledgement of a plurality of views, including possibly dissonant goals 
(5) a balancing of different perspectives and, ideally, reaching of a shared agreement 
regarding the approach to symptom monitoring  
 
4. One size does not fit all 
 
We have argued previously5 and here that bodily sensations may cause fear and anxiety in 
individuals living beyond cancer, and that this fear may drive vigilance and symptom 
monitoring. However, every individual’s experience of survivorship is unique, and a 
consideration of symptom monitoring would be remiss without recognition of individual 
differences. For example, it is important to recognize that not all individuals living beyond 
cancer will engage in active symptom monitoring.  For some, FCR may be minimal. For 
others, especially those for whom cancer was relatively asymptomatic, bodily sensations 
may not be a key source of concern. In addition, whilst FCR may drive symptom monitoring 
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in some individuals, for others fear may prompt avoidance of surveillance altogether. In this 
case, an ethical argument could be made to increase symptom monitoring if appropriate 
and relevant for physical health.  Relatedly, within the context of the SDM framework, 
individuals with very high levels of FCR may describe being risk-averse as a highly rated 
value. Yet, for those individuals, being instructed to monitor symptoms could counter-
productively drive further fear and lower quality of life. In these cases, the agreements 
arising through SDM might need to change over the course of survivorship. That is, if 
individuals opt for a risk averse position, but this in turn leads increased fear and anxiety 
over time, a referral for treatment of FCR may be most appropriate35,36, followed by a 
renegotiation of decisions after successful treatment. Ultimately, it is important to 
recognize that there are well-documented vulnerable groups who are at higher risk of FCR 
(e.g., young women with breast cancer)37 and that extreme cases of symptom 
hypervigilance or negligence, as depicted in Figure 1, may be more highly represented in 
individuals with high FCR.   
 
Beyond individual differences in psychological responses to cancer, individual differences in 
disease state and risk of recurrence are also important.  First, risk of disease recurrence 
differs greatly among different cancers and depends largely on tumor biology, extent of 
disease, and treatment administered. Clinician communication about the patient’s 
individual risk for disease recurrence is increasingly recognized as an important part of 
follow-up care and is likely also important within the context of communication about 
symptom monitoring. For example, Janz and colleagues38 previously found that women 
living beyond breast cancer who reported receiving insufficient information about risk of 
recurrence subsequently reported a decrease in emotional wellbeing over time. Thus, these 
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authors, among others37, argue that communicating about individual risk of recurrence is 
warranted. Second, the extent to which physical symptoms are useful or reliable indicators 
of recurrence for that individual must be taken into consideration. There is evidence for 
some diseases, including breast cancer, that most symptoms arising after successful 
treatment are not due to cancer recurrence39. Moreover, in diseases such as localized 
prostate cancer, therapy completion is often accompanied by the development of long-term 
treatment-related side effects such as urinary and bowel dysfunction and associated 
physical symptomatology. For other diseases, (certain) symptoms may be more reliable 
indicators of disease recurrence.  
 
Third, there is also variability in whether early detection improves outcomes. In a recent 
review of the literature, Le and Tzeng40 noted that whilst early detection is not always 
associated with improved outcomes, there are clear instances (e.g., resection of liver and 
lung metastases in colorectal cancer) in which early detection and treatment are beneficial. 
Therefore, targeted monitoring for symptoms that may reflect treatable tumor recurrence 
may have value.  Fourth, there is also mixed evidence for the beneficial impact of symptom 
monitoring on physical and psychological well-being across different diseases. Within the 
context of active cancer treatment, symptom monitoring and reporting has largely been 
shown to have more benefit than harm1,2. In opposition, studies of men who have been 
successfully treated for prostate cancer indicate little positive impact of symptom 
monitoring interventions41. Interestingly, beyond detection of recurrence, research on the 
utility of survivorship care plans has identified where symptom monitoring may be 
particularly useful for certain demographic groups. For example, Faul and colleagues42 
indicate that older people may misattribute modifiable symptoms (e.g., late effects of 
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treatment) to “normal aging” or believe that their symptoms are not treatable. They thus 
argue for promoting active and guided symptom monitoring as part of survivorship care 
plans in this population. Taken together, individual differences in disease state are 
important to consider in weighing the relative risks and benefits of symptom monitoring. 
Within an SDM framework, it is important that the clinician provides clear communication 
about the individual’s status across these disease-related factors, in balance with 
recognizing and measuring psychological risk, in order to guide the clinician-patient 
discussion.  
 
5. Clinical examples and future steps 
Whilst recognizing the layers of individual difference and uncertainty described above, we 
propose specific points that are appropriate for clinicians to consider when broadly 
reflecting on how to best communicate with their patients about the challenge of symptom 
monitoring after cancer (see Panel 1). We also offer two clinical examples in which 
individual patient differences are taken into account and an SDM framework could be 
usefully employed. Of note, in the first example, clear communication about risk, 
recognition of psychological concerns, and reassurance regarding physical symptoms is 
sufficient, whereas in the second example a more specific symptom monitoring plan is 
developed.  
 
 
Example 1: Nathan is a 20-year-old young man who completed chemotherapy and radiation 
therapy for Ewing sarcoma in his pelvis 2 years previously. He was originally diagnosed after 
presenting with persistent sciatic pain and is now very vigilant and fearful when 
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experiencing changes in physical sensations, including pain, in the lower half of his body. His 
remembers a friend with Ewing sarcoma, whom he met in hospital, whose diseased 
metastasized to the lungs and subsequently proved fatal. Nathan is therefore also vigilant of 
changes to his breathing or a new cough. Nathan attends his scheduled follow-up sessions 
at the hospital but is reassured by learning that his scans are clear each time that he does 
not actively indicate difficulties with fear of recurrence or knowing how to appraise and 
cope with physical symptoms. 
Relevant doctor-patient communication 
1) Through routine screening of FCR, identify if Nathan has clinically high levels of FCR and 
consider referring him for psychological support  
2) Enquire as to whether Nathan is worrying about physical symptoms and if so, which 
ones 
3) Discuss with Nathan that whilst there is some risk of his disease recurring and there are 
certain symptoms that could be a cause for concern (e.g., persistent, worsening sciatic 
pain), other symptoms should not cause concern (e.g., a cough is not a symptom of early 
recurrence of Ewing sarcoma). Also mention that as he is receiving regular scans (every 3 
months), disease recurrence is likely to be detected before it becomes symptomatic 
4) Acknowledge that many individuals experience difficulty with symptom perception after 
cancer and that knowing how to appraise and respond to physical sensations is a 
significant challenge for both physical and psychological health 
5) Ensure that Nathan knows that the care team is available to help evaluate the 
significance of symptoms of concern to him, and can also assist him with psychological 
support if persistent worry interferes with quality of life or functioning  
15 
 
Example 2: Joanna is a 34-year-old woman who completed surgery, chemotherapy, and 
radiotherapy for primary breast cancer. She is scheduled to receive follow-up scans every 6 
months although has missed two appointments due to fear of finding out that her cancer 
has returned. Although her cancer was originally asymptomatic and was detected 
throughout routine surveillance, she is increasingly fearful of changes in physical sensations 
in her breasts and palpates her breasts every day to monitor for disease recurrence.   
Relevant doctor-patient communication 
1) Through routine screening of FCR, identify if Joanna has clinically high levels of FCR and 
consider referring her for psychological support  
2) Enquire as to whether Joanna is worrying about physical symptoms and if so, which ones 
3) Reassure Joanna regarding her relatively low risk of disease recurrence, and review 
symptoms of concern and non-concern 
4) Acknowledge that many individuals experience difficulty with symptom perception after 
cancer and that knowing how to appraise and respond to physical sensations is a 
significant challenge for both physical and psychological health 
5) Discuss with Joanna that examining her breast tissue every day is likely to cause 
soreness that is unrelated to disease recurrence. Develop a behavioral contract in which 
Joanna agrees to attend her 6-monthly scans but in between each scan to reduce the 
number of times she checks her breasts from once per day to once per month 
 
Our proposed framework and points for consideration are not recommended as definitive 
solutions.  Instead, our aim is to raise awareness of the potential quality-of-life implications 
of symptom monitoring practices, to recognize the need for a balance between physical and 
psychological health in cancer survivorship, and to generate cross-discipline discussion on 
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the medical, psychological, and ethical challenges of symptom monitoring after cancer.  
There are a number of future steps and research questions to guide continued discussion. 
First, we suggest above that screening for FCR is likely essential for successful employment 
of an SDM framework. A number of brief instruments indicating good reliability and validity 
are available for this purpose. For example, the Fear of Cancer Recurrence Inventory 
severity subscale comprises only nine items and provides clinical cutoffs to identify 
individuals with clinically high levels of FCR. The published cut-off score indicates that > 13 is 
a “clinical” range, however, recent work suggests that a score of 22 or above is more likely 
to indicate a need for referral to a psycho-oncology specialist43. There is also now some 
evidence to support a 4-item measure44. However, there are no measures of FCR developed 
for or validated in children and adolescents. There are also no measures of fear of physical 
symptoms within the context of cancer survivorship. The development of pediatric and 
symptom-specific measures of FCR is an important next step to guide both research and 
clinical practice. Second, a wide survey of clinician beliefs, attitudes, and behaviors 
(communication strategies) regarding symptom monitoring after cancer treatment 
cessation is needed. Particularly useful will be survey data encompassing multiple disciplines 
(e.g., oncologists and psychologists working in oncology settings), clinical environments 
(private and public medical institutions), and international settings. The latter is particularly 
relevant given that the degree of routine surveillance, and relative reliance on physical 
symptoms to guide follow-up scans and tests, differ greatly between countries. Third, 
qualitative studies of patient experiences in coping with uncertainty around bodily 
sensations after cancer, and in communicating with clinicians about symptom monitoring, 
will be revealing. Overall, we need to understand the range of clinician communication 
practices about symptom monitoring, the impact of this communication on patient 
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wellbeing, the clinician’s subjective level of comfort in weighing physical and psychological 
risks, and their interest in receiving training to enhance shared decision-making within this 
context.  
  
6. Acting in uncertainty 
Many clinical decisions involve acting in uncertainty. In the case of directed symptom 
monitoring after cancer, and how clinicians communicate about this practice, such 
uncertainty has several layers. One layer involves the individual’s risk of disease recurrence, 
the extent to which physical symptoms are useful or reliable indicators of recurrence for 
that individual, and the timeframe within which these symptoms are associated with a 
curable or symptom-relieving disease state. As techniques for recurrence detection through 
routine surveillance improve, the clinical need for patient-driven symptom monitoring will 
likely decrease. Also relevant is the extent to which physical symptoms are reliable 
indicators of late effects of cancer treatment beyond disease recurrence, such as cardio-
pulmonary health and fertility issues. We have not addressed these issues within this paper, 
but we note that their consideration is relevant for guiding best practices in clinician 
communication surrounding directed symptom monitoring. Another layer concerns the 
physician’s own tolerance of uncertainty. We highlight the important role that the clinician 
has in providing counselling about symptom monitoring. Yet, we recognize that this role can 
be difficult to navigate. Just like patients have variable risk tolerance, comfort with 
uncertainty, and degree of worry, so do physicians.  It is both the physician’s clinical 
experience and their own psychological milieu that affects how they view data (such as 
reported symptoms), weigh perceived risks for the patient, and make recommendations. In 
the presence of a patient reporting symptom-related concerns, the clinician may feel 
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obligated to ‘do everything’, leading to potentially unnecessary testing and biopsies, each of 
which can increase fear at least temporarily. Failing to ‘do everything’ may be viewed as not 
taking the patients’ symptom-related concerns seriously, further contributing to issues of 
epistemic (in)justice described earlier. On the other hand, providing anticipatory guidance 
about the meaning of specific symptoms may be important in decreasing both (hyper-
)vigilance and negligence. Eliciting an understanding of the patient’s worries may permit the 
clinician to identify misperception and relieve misplaced worry.  As a clinician, being aware 
of your own biases as you approach shared decision making with patients may be as 
important as understanding the patient’s perspective. 
 
7. Conclusion 
Life beyond cancer for many is like living next to a volcano, in the shadow of an ever- 
present, uncontrollable threat. To ignore the smoke would be to miss what little 
information is available, even when one knows it can be unreliable. Attending only to the 
smoke, however, brings the risk of chronic preoccupation with threat, heightened fear, and 
decreased well-being. In this Personal View article, we have considered the role of the 
clinician in providing guidance for individuals living beyond cancer as they navigate this 
uncertain environment. We propose a shared decision-making approach that encourages a 
discussion of the magnitude of the individual’s cancer recurrence risks the relative reliability 
of symptoms for that individual, as well as psychosocial considerations of fear of cancer 
recurrence and mental health. Instead of a choice between a ‘better safe than sorry’ or 
‘wait and see’ strategy, we propose an alternative, ethically pragmatic strategy in which one 
promotes the opportunity to acknowledge the plurality of values as well as ethical and 
personal preferences described above, and engages in shared decision-making that respects 
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the individual’s chosen approach to symptom monitoring. We intend not to offer a 
definitive solution but instead to generate cross-disciplinary discussion on the medical, 
psychological, and ethical challenges of symptom monitoring after cancer in order to guide 
clinical practice.  
 
SEARCH STRATEGY AND SELECTION CRITERIA 
We identified references for this Personal View article by searching PubMed and Google 
Scholar with the search terms “symptom monitoring”, “surveillance”, “shared decision 
making”, “cancer”, and “cancer survivors” at several stages during both the writing of the 
initial manuscript and in responding to reviewer comments. We also searched reference 
lists of papers that were identified as particularly relevant from the PubMed search. As this 
is not a systematic review, we included only the most relevant articles and review papers as 
well as individual smaller studies that provided nuanced perspectives.  
 
AUTHOR CONTRBUTIONS  
All authors contributed to the writing and editing of this paper. LCH was the primary writer. 
DSG and BDE led the section on shared decision-making. LCH and CE led the remaining 
sections. LS contributed to the discussion of fear of cancer recurrence. SLS provided 
guidance for considerations of clinical practice. LCH and LES developed Figure 1. 
 
DECLARATION OF INTERESTS 
There are no financial or personal conflicts of interest to declare. All authors report nothing 
to disclose.  
 
20 
 
FUNDING STATEMENT 
There are no funding sources for this article. 
 
FIGURE LEGENDS 
Figure 1. A shared decision-making (SDM) framework for symptom monitoring in cancer 
survival. 
 
REFERENCES 
1 Basch E, Deal AM, Dueck AC, et al. Overall Survival Results of a Trial Assessing Patient-
Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment. 
JAMA 2017; 318: 197. 
2 Basch E, Deal AM, Kris MG, et al. Symptom monitoring with patient-reported 
outcomes during routine cancer treatment: A randomized controlled trial. J Clin Oncol 
2016; 34: 557–65. 
3 Garofalo JP, Choppala S, Hamann HA, Gjerde J. Uncertainty during the transition from 
cancer patient to survivor. Cancer Nurs 2009; 32. 
DOI:10.1097/NCC.0b013e31819f1aab. 
4 Miller LE. Sources of uncertainty in cancer survivorship. J Cancer Surviv 2012; 6: 431–
40. 
5 Heathcote LC, Eccleston C. Pain and cancer survival : a cognitive-affective model of 
symptom appraisal and the uncertain threat of disease recurrence. Pain 2017; 158: 
1187–91. 
6 Wang JW, Shen Q, Ding N, et al. A qualitative exploration of the unmet psychosocial 
rehabilitation needs of cancer survivors in China. Psychooncology 2016; 25: 905–12. 
21 
 
7 Hanprasertpong J, Geater A, Jiamset I, Padungkul L, Hirunkajonpan P, Songhong N. 
Fear of cancer recurrence and its predictors among cervical cancer survivors. J 
Gynecol Oncol 2017; 28: e72. 
8 Gärtner R, Jensen M-B, Nielsen J, Ewertz M, Kroman N, Kehlet H. Prevalence of and 
factors associated with persistent pain following breast cancer surgery. JAMA 2009; 
302: 1985–92. 
9 Polomano RC, Farrar JT. Pain and Neuropathy in Cancer Survivors: Surgery, radiation, 
and chemotherapy can cause pain; research could improve its detection and 
treatment. AJN Am J Nurs 2006; 106. 
10 Miltenburg NC, Boogerd W. Chemotherapy-induced neuropathy: A comprehensive 
survey. Cancer Treat. Rev. 2014; 40: 872–82. 
11 Harrington CB, Hansen J a, Moskowitz M, Todd BL, Feuerstein M. It’s not over when 
it’s over: long-term symptoms in cancer survivors--a systematic review. Int J 
Psychiatry Med 2010; 40: 163–81. 
12 Simard S, Thewes B, Humphris G, et al. Fear of cancer recurrence in adult cancer 
survivors: A systematic review of quantitative studies. J Cancer Surviv 2013; 7: 300–
22. 
13 Paice JA, Portenoy R, Lacchetti C, et al. Management of chronic pain in survivors of 
adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin 
Oncol 2016; 34: 3325–45. 
14 Longo MR, Iannetti GD, Mancini F, Driver J, Haggard P. Linking Pain and the Body: 
Neural Correlates of Visually Induced Analgesia. J Neurosci 2012; 32: 2601–7. 
15 Moseley GL, Arntz A. The context of a noxious stimulus affects the pain it evokes. Pain 
2007; 133: 64–71. 
22 
 
16 Mancini F, Longo MR, Kammers MPM, Haggard P. Visual distortion of body size 
modulates pain perception. Psychol Sci 2011; 22: 325–30. 
17 Moseley GL, Parsons TJ, Spence C. Visual distortion of a limb modulates the pain and 
swelling evoked by movement. Curr Biol 2008; 18: 1047–8. 
18 Stanton TR, Moseley GL, Wong AYL, Kawchuk GN. Feeling stiffness in the back: A 
protective perceptual inference in chronic back pain. Sci Rep 2017; 7. 
DOI:10.1038/s41598-017-09429-1. 
19 Crombez G, Eccleston C, Van Damme S, Vlaeyen JWS, Karoly P. Fear-avoidance model 
of chronic pain: the next generation. Clin J Pain 2012; 28: 475–83. 
20 Leeuw M, Goossens MEJB, Linton SJ, Crombez G, Boersma K, Vlaeyen JWS. The fear-
avoidance model of musculoskeletal pain: Current state of scientific evidence. J Behav 
Med 2007; 30: 77–94. 
21 Vlaeyen JWS, Linton SJ. Fear-avoidance and its consequences in chronic 
musculoskeletal pain: A state of the art. Pain 2000; 85: 317–32. 
22 Rhudy JL, Meagher MW. Fear and anxiety: divergent effects on human pain 
thresholds. Pain 2000; 84: 65–75. 
23 Armes J, Crowe M, Colbourne L, et al. Patients’ supportive care needs beyond the end 
of cancer treatment: A prospective, longitudinal survey. J Clin Oncol 2009; 27: 6172–
9. 
24 Lebel S, Ozakinci G, Humphris G, et al. From normal response to clinical problem: 
definition and clinical features of fear of cancer recurrence. Support Care Cancer 
2016; 24: 3265–8. 
25 Butow P, Kelly S, Thewes B, Hruby G, Sharpe L, Beith J. Attentional bias and 
metacognitions in cancer survivors with high fear of cancer recurrence. 
23 
 
Psychooncology 2015; 24: 416–23. 
26 Kehl KL, Landrum MB, Arora NK, et al. Association of Actual and Preferred Decision 
Roles With Patient-Reported Quality of Care. JAMA Oncol 2015; 1: 50. 
27 Stacey D, Légaré F, Lewis K, et al. Decision aids for people facing health treatment or 
screening decisions. Cochrane Database Syst. Rev. 2017. 
28 Shay AL, Lafata JE. Where is the evidence? A systematic review of shared decision 
making and patient outcomes. Med Decis Mak 2015; 35: 114–31. 
29 Barry MJ, Edgman-Levitan S. Shared Decision Making — The Pinnacle of Patient-
Centered Care. N Engl J Med 2012; 366: 780–1. 
30 Katz J. The silent world of doctor and patient. Johns Hopkins University Press, 2002. 
31 Buchman DZ, Ho A, Goldberg DS. Investigating Trust, Expertise, and Epistemic 
Injustice in Chronic Pain. J Bioeth Inq 2017; 14: 31–42. 
32 Williams AC de C. Defeating the stigma of chronic pain. Pain 2016; 157: 1581–2. 
33 Earp BD, Darby R. Circumcision, sexual experience, and harm. Univ Pennsylvania J Int 
Law 2017; 37: 1–57. 
34 Powers M, Faden R. Social Justice: The Moral Foundations of Public Health and Health 
Policy. In: Social Justice: The Moral Foundations of Public Health and Health Policy. 
2008: 15–49. 
35 Humphris G, Rogers S. AFTER and beyond:cancer recurrence fears and a test of an 
intervention in oral and oropharyngeal patients. Soc Sci Dent 2012; 2: 29–38. 
36 van de Wal M, Thewes B, Gielissen M, Speckens A, Prins J. Efficacy of Blended 
Cognitive Behavior Therapy for High Fear of Recurrence in Breast, Prostate, and 
Colorectal Cancer Survivors: The SWORD Study, a Randomized Controlled Trial. J Clin 
Oncol 2017; 35: 2173–83. 
24 
 
37 Butow P, Sharpe L, Thewes B, Turner J, Gilchrist J, Beith J. Fear of Cancer Recurrence: 
A Practical Guide for Clinicians. Oncol J 2018; 32: 32–8. 
38 Janz NK, Friese CR, Li Y, Graff JJ, Hamilton AS, Hawley ST. Emotional well-being years 
post-treatment for breast cancer: Prospective, multi-ethnic, and population-based 
analysis. J Cancer Surviv 2014; 8: 131–42. 
39 Ghezzi P, Magnanini S, Rinaldini M, Al E. Impact of follow-up testing on survival and 
health-related quality of life in breast cancer patients: A multicenter randomized 
controlled trial. JAMA 1994; 271: 1587–92. 
40 Le A, Tzeng CD. Does finding early recurrence improve outcomes, and at what cost? J 
Surg Oncol 2016; 114: 329–35. 
41 M Davis K, Dawson D, Kelly S, et al. Monitoring of health-related quality of life and 
symptoms in prostate cancer survivors: a randomized trial. 2013. 
42 Faul LA, Luta G, Sheppard V, et al. Associations among survivorship care plans, 
experiences of survivorship care, and functioning in older breast cancer survivors: 
CALGB/Alliance 369901. J Cancer Surviv 2014; 8: 627–37. 
43 Fardell JE, Jones G, Smith A Ben, et al. Exploring the screening capacity of the Fear of 
Cancer Recurrence Inventory-Short Form for clinical levels of fear of cancer 
recurrence. Psychooncology 2018; 27: 492–9. 
44 Humphris GM, Watson E, Sharpe M, Ozakinci G. Unidimensional scales for fears of 
cancer recurrence and their psychometric properties: The FCR4 and FCR7. Health 
Qual Life Outcomes 2018; 16. DOI:10.1186/s12955-018-0850-x. 
 
